title: [Comparative study of heterogeneity of extranodal and nodal diffuse large B cell lymphoma].
abstract: OBJECTIVE
  Primary nodal and extranodal diffuse large B-cell lymphoma (DLBCL) were investigated for the heterogeneity of histopathology and immunophenotype, and their relation to clinical stage, comparatively. Whether E2F1 can be used as a germinal center B cell (GCB) DLBCL marker was also discussed.
  
  
  METHODS
  Classification of histopathology and immunophenotype of 98 cases were studied by immunohistochemistry in tissue microarray.
  
  
  RESULTS
  Histopathologic morphology presented as: centroblastic (CB,88.8%, 87/98), immunoblastic (IB,5.1%, 5/98), anaplastic (ALCL,3.1%, 3/98), and T cell rich B cell lymphoma (TCRBCL,3.1%, 3/98). Of which, 31 cases were GCB DLBCL, 10 (20.8%, 10/48) nodal, and 21 extranodal (42%, 21/50, P=0.024). The rates of Stages I/II in nodal and extranodal area were 48.5% and 70%, respectively (P=0.015). The rate of Stage I/ II in GCB DLBCL (74.2%) were higher than in non-GCB DLBCL (50.7%, P=0.029). The CD10 positive rates were 36.8% and 17.1% in Stages I/II and III/IV, respectively, and had significant differences (P=0.033). The CD10 positive rates were 18.8% and 38% in nodal and extranodal area, respectively (P=0.035). The positive rates of E2F1 were 38.8% and 16.5% in GCB and non-GCB DLBCL, respectively, and had significant differences (P=0.016). The positive rate of E2F1 had positive relation with the expression of CD10 and Bcl-6 (P<0.05).
  
  
  CONCLUSIONS
  CB is the most type in 98 cases of DLBCL. The rate of GCB DLBCL was significant higher in extranodal than in nodal areas CD 10 can be used as a prognostic marker. The prognosis of GCB DLBCL is better than that of non-GCB DLBCL. The positive expression of E2F1 can be used as a marker of GCB DLBCL.
authors: Department of Pathology, Peking University First Hospital, Beijing 100034, China. yinhf@hotmail.com
authors: Hong-fang
authors: HF
authors: Yin
authors: Ting
authors: T
authors: Li
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis*; D050687:E2F1 Transcription Factor / Q000032:analysis; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D050835:Interferon Regulatory Factors / Q000032:analysis; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology*; D008297:Male; D015260:Neprilysin / Q000032:analysis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000032:analysis; D000099218:Interferon Regulatory Factor-4
chemical_list: D014408:Biomarkers, Tumor; D050687:E2F1 Transcription Factor; D050835:Interferon Regulatory Factors; D015260:Neprilysin; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6; D000099218:Interferon Regulatory Factor-4; C493753:E2F1 protein, human